信迪利单抗同步化学治疗联合呼吸操康复训练治疗晚期非小细胞肺癌临床观察  

Clinical Observation of Synchronous Chemotherapy with Sintilimab Combined with Respiratory Rehabilitation Training in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：王静[1] 高丽萍[1] 陈冬梅 WANG Jing;GAO Liping;CHEN Dongmei(Qidong People's Hospital·Qidong Institute of Liver Cancer Prevention and Treatment,Nantong,Jiangsu,China 226200)

机构地区：[1]江苏省启东市人民医院·启东肝癌防治研究所,江苏南通226200

出　　处：《中国药业》2024年第23期95-99,共5页China Pharmaceuticals

基　　金：江苏省科研基金资助项目[2022HG002673]。

摘　　要：目的探讨信迪利单抗同步化学治疗(简称化疗)联合呼吸操康复训练治疗晚期非小细胞肺癌(NSCLC)的临床疗效,以及对患者肺功能和生活质量的影响。方法选取医院2021年1月至2023年12月收治的晚期NSCLC患者110例,按随机数字表法分为观察组和对照组,各55例。两组患者均予常规治疗,对照组患者在此基础上予信迪利单抗同步化疗,观察组患者在对照组治疗基础上增加呼吸操康复训练,化疗均持续4个周期,呼吸操康复训练持续3个月。结果观察组的客观缓解率和疾病控制率分别为56.36%和92.73%,均显著高于对照组的36.36%和78.18%(P<0.05)。治疗后,两组患者的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积、FEV1/FVC],缺氧相关指标(动脉血氧饱和度、动脉血氧分压),免疫功能指标(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),以及癌症治疗功能评价系统-肺癌模块(FACT-L)评分均较治疗前显著升高(P<0.05),且观察组升高幅度均显著大于对照组(P<0.05);两组患者的肺功能指标(缺氧诱导因子-1α)、免疫功能指标(CD8^(+))均较治疗前显著降低(P<0.05),且观察组降低幅度均显著大于对照组(P<0.05)。观察组和对照组患者的不良反应发生率相当(14.55%比10.91%,P>0.05)。结论信迪利单抗同步化疗联合呼吸操康复训练治疗晚期NSCLC的临床疗效良好,可提升患者的肺功能,改善缺氧程度,提高免疫功能和生活质量,且安全性良好。Objective To investigate the clinical efficacy of synchronous chemotherapy with sintilimab combined with respiratory rehabilitation training in the treatment of advanced non-small cell lung cancer(NSCLC),and its effect on patients′lung function and quality of life.Methods A total of 110 patients with advanced NSCLC admitted to the hospital from January 2021 to December 2023 were selected and randomly divided into the observation group and the control group by the random number table method,with 55 cases in each group.The patients in the two groups received routine treatment,while the patients in the control group received synchronous chemotherapy with sintilimab,and the patients in the observation group received respiratory exercise rehabilitation training on the basis of the control group,with chemotherapy lasting for four cycles and respiratory exercise rehabilitation training lasting for three months.Results The objective remission rate and disease control rate in the observation group were 56.36%and 92.73%,which were significantly higher than 36.36%and 78.18%in the control group(P<0.05).After treatment,the lung function indicators[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC],hypoxia-related indicators[arterial oxygen saturation(SaO2),arterial partial pressure of oxygen(PaO2)],immune function indicators(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),and functional assessment of cancer therapy-lung(FACT-L)score in the two groups were significantly higher than those before treatment(P<0.05),and those in the observation group were significantly higher than those in the control group(P<0.05);the lung function indicators[hypoxia-inducible factor-1α(HIF-1α)]and immune function indicator(CD8^(+))in the two groups were significantly lower than those before treatment(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions between the observation group and the control group was comparable(14.55%vs.10.9

关 键 词：信迪利单抗 呼吸操康复训练 非小细胞肺癌 肺功能 生活质量 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]